ProCE Banner Activity

FAQs: Optimal Selection and Sequencing of Treatment for Patients With Aggressive B-Cell Lymphomas

Clinical Thought

In this commentary, expert faculty address frequently asked questions about the selection and sequencing of therapies for patients with aggressive B-cell lymphomas.

Released: January 31, 2023

Expiration: January 30, 2024

No longer available for credit.

Share

Faculty

John Allan

John Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John P. Leonard

John P. Leonard, MD

Senior Associate Dean for Innovation and initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

Laurie H. Sehn

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer
Vancouver, Canada

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genmab US Inc and AbbVie

Karyopharm Therapeutics Inc.

Regeneron Pharmaceuticals, Inc.

Disclosure

John N. Allan, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Epizyme, Genentech, Janssen, Pharmacyclics.

John P. Leonard, MD: consulting/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Calithera, Caribou Biosciences, Constellation, Eisai, Epizyme, Genmab, Grail, Incyte, Janssen, Karyopharm, Lilly, Merck, Mustang Bio, Pfizer, Roche/Genentech, Second Genome, Sutro.

Laurie H. Sehn, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Gilead/Kite, Incyte, Janssen, Merck, Roche/Genentech, Seattle Genetics, Teva, TG Therapeutics.